| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 15.3332 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 15.3332. The average price that 007390.KQ shares were previous bought at was KRW 21.4176. The current market price is -28.4% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 1,964 (USD $1) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 30.4596 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 30.4596. The average price that 039200.KQ shares were previous bought at was KRW 21.0043. The current market price is 45.0% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 35,066 (USD $24) compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 125.422 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 125.422. The average price that 068270.KS shares were previous bought at was KRW 121.694. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in 068270.KS has increased by KRW 277,672 (USD $188) compared to the previous valuation of CELLTRION INC however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.9182 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.9182. The average price that 096530.KQ shares were previous bought at was KRW 17.6933. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 16,182 (USD $11) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.66481 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.66481. The average price that 13.HK shares were previous bought at was HKD 3.01399. The current market price is -11.6% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 3,817 (USD $491) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.96732 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 2.90146 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 2.90146. The average price that 1877.HK shares were previous bought at was HKD 2.51798. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 21,807 (USD $2,804) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1165.32 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1165.32. The average price that 207940.KS shares were previous bought at was KRW 760.081. The current market price is 53.3% higher than average price they were purchased at. The value of the holding in 207940.KS has increased by KRW 78,609 (USD $53) compared to the previous valuation of SAMSUNG BIOLOGICS LTD however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 6.9707 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 6.9707. The average price that 2162.HK shares were previous bought at was HKD 5.35965. The current market price is 30.1% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 19,361 (USD $2,490) compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.72655 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.72655. The average price that 2252.HK shares were previous bought at was HKD 3.16268. The current market price is -13.8% lower than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 20,319 (USD $2,613) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 86.0726 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 86.0726. The average price that 237690.KQ shares were previous bought at was KRW 55.5458. The current market price is 55.0% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 28,180 (USD $19) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 129.212 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 129.212. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 221.5% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 133,296 (USD $90) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 34.5945 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 34.5945. The average price that 302440.KS shares were previous bought at was KRW 36.2275. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in 302440.KS has increased by KRW 13,354 (USD $9) compared to the previous valuation of SK BIOSCIENCE LTD however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 87.5198 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 87.5198. The average price that 326030.KS shares were previous bought at was KRW 77.4592. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 31,282 (USD $21) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 30.6664 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 30.6664. The average price that 328130.KQ shares were previous bought at was KRW 36.3011. The current market price is -15.5% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 50,907 (USD $34) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.54333 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.54333. The average price that 3933.HK shares were previous bought at was HKD 1.67688. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 11,779 (USD $1,515) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.5745 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.5745. The average price that 4523.T shares were previous bought at was JPY 28.5269. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 157,047 (USD $1,006) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.5381 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.5381. The average price that 4549.T shares were previous bought at was JPY 13.728. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 4,940 (USD $32) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.3427 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.3427. The average price that 4587.T shares were previous bought at was JPY 11.127. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 21,686 (USD $139) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.0183 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.0183. The average price that 4887.T shares were previous bought at was JPY 13.195. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in 4887.T has fallen by JPY 18,641 (USD $119) compared to the previous valuation of Sawai Group Holdings Co., Ltd. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.11521 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.11521. The average price that 4974.T shares were previous bought at was JPY 5.75157. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 6,962 (USD $45) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.99936 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.99936. The average price that 6869.T shares were previous bought at was JPY 14.9756. The current market price is -33.2% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 59,024 (USD $378) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 32.4819 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 32.4819. The average price that 6951.T shares were previous bought at was JPY 33.0489. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 54,510 (USD $349) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.1341 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.1341. The average price that 7575.T shares were previous bought at was JPY 10.1423. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 4,465 (USD $29) compared to the previous valuation of Japan Lifeline Co., Ltd. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.6362 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.6362. The average price that 7701.T shares were previous bought at was JPY 26.4723. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 2,339 (USD $15) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.9269 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.9269. The average price that 7747.T shares were previous bought at was JPY 16.8906. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 12,361 (USD $79) compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 9.77442 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 9.77442. The average price that 9995.HK shares were previous bought at was HKD 9.70899. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 34,268 (USD $4,406) compared to the previous valuation of REMEGEN LTD H |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 138.32 | USD 0 | The current share valuation price of A based on adjusted close was USD 138.32. The average price that A shares were previous bought at was USD 122.269. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in A has fallen by USD 4,896 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 229.89 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 229.89. The average price that ABBV shares were previous bought at was USD 201.245. The current market price is 14.2% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 85,641 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.72 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.72. The average price that ABCL shares were previous bought at was USD 3.61385. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 8,272 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.81 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.81. The average price that ABT shares were previous bought at was USD 124.674. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in ABT has increased by USD 29,697 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 27.87 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 27.87. The average price that ACAD shares were previous bought at was USD 20.1364. The current market price is 38.4% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 5,969 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 66 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 66. The average price that ACLX shares were previous bought at was USD 64.8725. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 24,718 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.68 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.68. The average price that ADPT shares were previous bought at was USD 6.89362. The current market price is 142.0% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 12,746 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 28.52 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 28.52. The average price that ALKS shares were previous bought at was USD 30.7179. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 5,927 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 333.96 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 333.96. The average price that AMGN shares were previous bought at was USD 296.507. The current market price is 12.6% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 124,179 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.49 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.49. The average price that AMLX shares were previous bought at was USD 13.5196. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in AMLX has increased by USD 15,902 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 50.01 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 50.01. The average price that ANAB shares were previous bought at was USD 23.8129. The current market price is 110.0% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 773 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.50002 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.50002. The average price that ARCT shares were previous bought at was USD 13.0207. The current market price is -50.1% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 1,817 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.17 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.17. The average price that ARVN shares were previous bought at was USD 11.3626. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in ARVN has fallen by USD 843 compared to the previous valuation of Arvinas Inc |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 25.12 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 25.12. The average price that ASTH shares were previous bought at was USD 26.5685. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in ASTH has increased by USD 32,839 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 40.55 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 40.55. The average price that ATRC shares were previous bought at was USD 33.402. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in ATRC has increased by USD 591 compared to the previous valuation of AtriCure Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.275 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.275. The average price that AUPH shares were previous bought at was USD 11.2153. The current market price is 45.1% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 10,323 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 32.64 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 32.64. The average price that AXGN shares were previous bought at was USD 18.047. The current market price is 80.9% higher than average price they were purchased at. The value of the holding in AXGN has fallen by USD 10,524 compared to the previous valuation of Axogen Inc |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 153.64 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 153.64. The average price that AXSM shares were previous bought at was USD 116.831. The current market price is 31.5% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 25,272 compared to the previous valuation of Axsome Therapeutics Inc |
| BANB.SW - | HOLD | 0 @ CHF 75.3629 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 75.3629. The average price that BANB.SW shares were previous bought at was CHF 65.0923. The current market price is 15.8% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 3,565 (USD $4,527) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 29.873 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 29.873. The average price that BAVA.CO shares were previous bought at was DKK 25.4205. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 712 (USD $112) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.7 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.7. The average price that BCRX shares were previous bought at was USD 7.74854. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 43,772 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 28.14 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 28.14. The average price that BEAM shares were previous bought at was USD 18.6816. The current market price is 50.6% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 45,203 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 176.33 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 176.33. The average price that BIIB shares were previous bought at was USD 130.477. The current market price is 35.1% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 164,422 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 129.564 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 129.564. The average price that BIM.PA shares were previous bought at was EUR 121.406. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 29,735 (USD $35,074) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 301.75 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 301.75. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 18,437 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 301.75 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 301.75. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 18,437 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 34.9355 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 34.9355. The average price that BIOA-B.ST shares were previous bought at was SEK 29.997. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 3,215 (USD $351) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 25.41 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 25.41. The average price that BLFS shares were previous bought at was USD 25.7305. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 2,806 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 54.71 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 54.71. The average price that BMY shares were previous bought at was USD 53.3317. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 126,947 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 96.13 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.13. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 5,942 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 96.13 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.13. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 5,942 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 19.73 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 19.73. The average price that CDNA shares were previous bought at was USD 19.212. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in CDNA has fallen by USD 17,862 compared to the previous valuation of Caredx Inc |
| CERT - Certara Inc | HOLD | 0 @ USD 8.91 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.91. The average price that CERT shares were previous bought at was USD 10.4074. The current market price is -14.4% lower than average price they were purchased at. The value of the holding in CERT has fallen by USD 8,385 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 40.14 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 40.14. The average price that CGON shares were previous bought at was USD 41.6925. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in CGON has increased by USD 6,680 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 107.776 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 107.776. The average price that CHEMM.CO shares were previous bought at was DKK 78.2284. The current market price is 37.8% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 571 (USD $90) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 24.45 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 24.45. The average price that CPRX shares were previous bought at was USD 22.4325. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in CPRX has increased by USD 32,486 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CRL - Creightons Plc | HOLD | 0 @ USD 203.16 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 203.16. The average price that CRL shares were previous bought at was USD 165.907. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in CRL has increased by USD 17,106 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 68.88 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 68.88. The average price that CRVL shares were previous bought at was USD 111.522. The current market price is -38.2% lower than average price they were purchased at. The value of the holding in CRVL has increased by USD 29,845 compared to the previous valuation of CorVel Corp however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 40.09 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 40.09. The average price that CSTL shares were previous bought at was USD 21.3129. The current market price is 88.1% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 3,807 compared to the previous valuation of Castle Biosciences Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.07 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.07. The average price that CTKB shares were previous bought at was USD 5.7145. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in CTKB has increased by USD 4,715 compared to the previous valuation of Cytek Biosciences Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.6 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.6. The average price that DAWN shares were previous bought at was USD 8.3429. The current market price is 15.1% higher than average price they were purchased at. The value of the holding in DAWN has fallen by USD 2,740 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| DHR - Danaher Corporation | HOLD | 0 @ USD 231.47 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 231.47. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 46,597 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 231.47 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 231.47. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 46,597 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 78.4684 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 78.4684. The average price that DIA.MI shares were previous bought at was EUR 54.1257. The current market price is 45.0% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 726 (USD $856) compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 15.38 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 15.38. The average price that DVAX shares were previous bought at was USD 12.6313. The current market price is 21.8% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 602,280 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 67.42 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 67.42. The average price that DXCM shares were previous bought at was USD 78.8148. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 97,399 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 11.3142 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 11.3142. The average price that DYVOX.ST shares were previous bought at was SEK 6.29712. The current market price is 79.7% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 2,603 (USD $284) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.13172 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.13172. The average price that EKTA-B.ST shares were previous bought at was SEK 5.63298. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 5,137 (USD $561) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 12.08 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 12.08. The average price that EMBC shares were previous bought at was USD 13.0183. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in EMBC has increased by USD 11,028 compared to the previous valuation of Embecta Corp however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 17.6324 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 17.6324. The average price that EUZ.DE shares were previous bought at was EUR 18.7965. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in EUZ.DE has increased by EUR 270 (USD $318) compared to the previous valuation of Eckert & Ziegler SE however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.13 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.13. The average price that EVH shares were previous bought at was USD 9.55347. The current market price is -56.8% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 3,805 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.34625 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.34625. The average price that EVT.DE shares were previous bought at was EUR 6.56761. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 338 (USD $399) compared to the previous valuation of Evotec SE however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.29 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.29. The average price that EW shares were previous bought at was USD 74.591. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in EW has increased by USD 11,677 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.54 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.54. The average price that EXAS shares were previous bought at was USD 62.0439. The current market price is 63.7% higher than average price they were purchased at. The value of the holding in EXAS has fallen by USD 11,316 compared to the previous valuation of EXACT Sciences Corporation |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 46.51 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 46.51. The average price that EXEL shares were previous bought at was USD 38.1215. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in EXEL has fallen by USD 32,717 compared to the previous valuation of Exelixis Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 17.7 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 17.7. The average price that FTRE shares were previous bought at was USD 10.5322. The current market price is 68.1% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 23,251 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 102.38 | USD 0 | The current share valuation price of GH based on adjusted close was USD 102.38. The average price that GH shares were previous bought at was USD 54.9629. The current market price is 86.3% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 17,836 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 125.67 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 125.67. The average price that GILD shares were previous bought at was USD 107.342. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 64,322 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 32.862 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 32.862. The average price that GLPG.AS shares were previous bought at was EUR 29.0814. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 2,571 (USD $3,033) compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 334.76 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 334.76. The average price that GMAB.CO shares were previous bought at was DKK 222.447. The current market price is 50.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 5,439 (USD $859) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.3869 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.3869. The average price that GSK.L shares were previous bought at was GBP 19.3589. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 57,136 (USD $77,211) compared to the previous valuation of GlaxoSmithKline PLC |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.41 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.41. The average price that HALO shares were previous bought at was USD 60.3305. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 7,391 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.78036 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.78036. The average price that HLUN-B.CO shares were previous bought at was DKK 6.0023. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 553 (USD $87) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.5 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.5. The average price that HOLX shares were previous bought at was USD 66.2934. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 83,796 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 38.49 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 38.49. The average price that HRMY shares were previous bought at was USD 32.6637. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in HRMY has increased by USD 2,633 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 12.66 | USD 0 | The current share valuation price of IART based on adjusted close was USD 12.66. The average price that IART shares were previous bought at was USD 20.1099. The current market price is -37.0% lower than average price they were purchased at. The value of the holding in IART has increased by USD 5,635 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.14 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.14. The average price that IBRX shares were previous bought at was USD 2.81966. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 10,983 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.68 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.68. The average price that IDYA shares were previous bought at was USD 23.8167. The current market price is 49.8% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 28,571 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 135.32 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 135.32. The average price that ILMN shares were previous bought at was USD 95.299. The current market price is 42.0% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 145,886 compared to the previous valuation of Illumina Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.87 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.87. The average price that IOVA shares were previous bought at was USD 2.41138. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in IOVA has increased by USD 16,595 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 141.342 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 141.342. The average price that IPN.PA shares were previous bought at was EUR 120.641. The current market price is 17.2% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 32,503 (USD $38,339) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 226.02 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 226.02. The average price that IQV shares were previous bought at was USD 162.435. The current market price is 39.1% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 80,338 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 577.15 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 577.15. The average price that ISRG shares were previous bought at was USD 536.021. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 5,293 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.31 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.31. The average price that JANX shares were previous bought at was USD 24.7281. The current market price is -42.1% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 13,052 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 207.78 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 207.78. The average price that JNJ shares were previous bought at was USD 170.984. The current market price is 21.5% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 188,596 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.49 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.49. The average price that KNSA shares were previous bought at was USD 40.3374. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 1,559 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.06 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.06. The average price that KURA shares were previous bought at was USD 10.711. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 25,306 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.47 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.47. The average price that LAB shares were previous bought at was USD 1.39779. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in LAB has fallen by USD 10,358 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 197.14 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 197.14. The average price that LGND shares were previous bought at was USD 126.392. The current market price is 56.0% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 5,799 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 63.08 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 63.08. The average price that LIVN shares were previous bought at was USD 46.485. The current market price is 35.7% higher than average price they were purchased at. The value of the holding in LIVN has fallen by USD 10,956 compared to the previous valuation of LivaNova PLC |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 66.68 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 66.68. The average price that LNTH shares were previous bought at was USD 76.9588. The current market price is -13.4% lower than average price they were purchased at. The value of the holding in LNTH has increased by USD 12,475 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 675.667 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 675.667. The average price that LONN.SW shares were previous bought at was CHF 640.611. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 17,992 (USD $22,848) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 97.27 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 97.27. The average price that MDT shares were previous bought at was USD 90.2193. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 33,543 compared to the previous valuation of Medtronic PLC |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 571.86 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 571.86. The average price that MEDP shares were previous bought at was USD 382.527. The current market price is 49.5% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 62,218 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 86.94 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 86.94. The average price that MMS shares were previous bought at was USD 75.2803. The current market price is 15.5% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 10,107 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 106.45 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 106.45. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 31.7% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 255,701 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 106.45 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 106.45. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 31.7% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 255,701 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 32.75 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 32.75. The average price that MRNA shares were previous bought at was USD 25.9653. The current market price is 26.1% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 213,365 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.91 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.91. The average price that MRUS shares were previous bought at was USD 56.564. The current market price is 71.3% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 775 compared to the previous valuation of Merus BV however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.3 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.3. The average price that MRVI shares were previous bought at was USD 2.97559. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 1,561 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.55 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.55. The average price that MYGN shares were previous bought at was USD 8.64702. The current market price is -24.3% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 1,088 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 146.93 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 146.93. The average price that NBIX shares were previous bought at was USD 127.74. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 41,385 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 7.14 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 7.14. The average price that NEOG shares were previous bought at was USD 9.99438. The current market price is -28.6% lower than average price they were purchased at. The value of the holding in NEOG has fallen by USD 2,575 compared to the previous valuation of Neogen Corporation |
| NEU.AX - | HOLD | 0 @ AUD 13.2159 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 13.2159. The average price that NEU.AX shares were previous bought at was AUD 8.87049. The current market price is 49.0% higher than average price they were purchased at. The value of the holding in NEU.AX has fallen by AUD 40,774 (USD $27,326) compared to the previous valuation of |
| NOVN.SW - | HOLD | 0 @ CHF 139.57 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 139.57. The average price that NOVN.SW shares were previous bought at was CHF 113.545. The current market price is 22.9% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 21,979 (USD $27,912) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 235.54 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 235.54. The average price that NTRA shares were previous bought at was USD 176.324. The current market price is 33.6% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 12,501 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 9.52 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 9.52. The average price that NUVB shares were previous bought at was USD 6.64051. The current market price is 43.4% higher than average price they were purchased at. The value of the holding in NUVB has increased by USD 52,442 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.94 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.94. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 25,290 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.94 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.94. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 25,290 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.44 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.44. The average price that NVCR shares were previous bought at was USD 16.4121. The current market price is -18.1% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 21,390 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.72755 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.72755. The average price that ONT.L shares were previous bought at was GBP 1.72772. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in ONT.L has fallen by GBP 12,744 (USD $17,222) compared to the previous valuation of Oxford Nanopore Technologies Ltd |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.88 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.88. The average price that PACB shares were previous bought at was USD 1.37661. The current market price is 36.6% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 21,671 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.03 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.03. The average price that PFE shares were previous bought at was USD 24.3485. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 91,064 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.6961 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.6961. The average price that PHARM.AS shares were previous bought at was EUR 0.896789. The current market price is 89.1% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 561 (USD $662) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 90.4 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 90.4. The average price that PHM.MC shares were previous bought at was EUR 87.1976. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 20,559 (USD $24,250) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 151.476 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 151.476. The average price that PME.AX shares were previous bought at was AUD 165.183. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 261,533 (USD $175,277) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 288.82 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 288.82. The average price that PODD shares were previous bought at was USD 282.956. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 163,955 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 274.76 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 274.76. The average price that PRAX shares were previous bought at was USD 167.342. The current market price is 64.2% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 23,766 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 78.37 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 78.37. The average price that PTCT shares were previous bought at was USD 56.4444. The current market price is 38.8% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 63,400 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 28.91 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 28.91. The average price that QDEL shares were previous bought at was USD 29.52. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in QDEL has increased by USD 25,546 compared to the previous valuation of Quidel Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 23.12 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 23.12. The average price that RCUS shares were previous bought at was USD 9.14068. The current market price is 152.9% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 36,021 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 165.66 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 165.66. The average price that RGEN shares were previous bought at was USD 145.299. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in RGEN has fallen by USD 44,073 compared to the previous valuation of Repligen Corporation |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 14.46 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 14.46. The average price that RGNX shares were previous bought at was USD 8.67354. The current market price is 66.7% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 5,842 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.65 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.65. The average price that RLAY shares were previous bought at was USD 5.08308. The current market price is 70.2% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 57,338 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 427.457 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 427.457. The average price that RO.SW shares were previous bought at was CHF 370.354. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 953 (USD $1,210) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 417.823 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 417.823. The average price that ROG.SW shares were previous bought at was CHF 324.411. The current market price is 28.8% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 22,762 (USD $28,906) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 96.78 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 96.78. The average price that RVTY shares were previous bought at was USD 100.003. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in RVTY has fallen by USD 113,131 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.4 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.4. The average price that RXRX shares were previous bought at was USD 5.14428. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 18,872 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 112.27 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 112.27. The average price that RYTM shares were previous bought at was USD 67.8137. The current market price is 65.6% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 5,548 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 18.38 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 18.38. The average price that SDGR shares were previous bought at was USD 22.5384. The current market price is -18.5% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 29,771 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 27.4946 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 27.4946. The average price that SECT-B.ST shares were previous bought at was SEK 28.0136. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 9,099 (USD $993) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 94.061 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 94.061. The average price that SFZN.SW shares were previous bought at was CHF 123.569. The current market price is -23.9% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 5,695 (USD $7,232) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 19.18 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 19.18. The average price that SLP shares were previous bought at was USD 26.1345. The current market price is -26.6% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 2,708 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 22.32 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 22.32. The average price that SRPT shares were previous bought at was USD 45.0034. The current market price is -50.4% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 38,470 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 289.162 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 289.162. The average price that SRT3.DE shares were previous bought at was EUR 247.576. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 2,599 (USD $3,066) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 32.17 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 32.17. The average price that STOK shares were previous bought at was USD 12.0607. The current market price is 166.7% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 19,970 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 51.77 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 51.77. The average price that SUPN shares were previous bought at was USD 36.2354. The current market price is 42.9% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 4,002 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 59.19 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 59.19. The average price that TECH shares were previous bought at was USD 59.3169. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in TECH has fallen by USD 11,285 compared to the previous valuation of Bio-Techne Corp |
| TECN.SW - | HOLD | 0 @ CHF 164.417 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 164.417. The average price that TECN.SW shares were previous bought at was CHF 197.12. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 3,197 (USD $4,060) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 31.07 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 31.07. The average price that TGTX shares were previous bought at was USD 33.8235. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in TGTX has increased by USD 58,490 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 579.12 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 579.12. The average price that TMO shares were previous bought at was USD 418.499. The current market price is 38.4% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 29,182 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 22.48 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 22.48. The average price that TNDM shares were previous bought at was USD 21.1386. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in TNDM has fallen by USD 11,513 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 33.58 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 33.58. The average price that TWST shares were previous bought at was USD 36.2456. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 17,568 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 16.69 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.69. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 33.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 24,914 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 16.69 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.69. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 33.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 24,914 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 277.384 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 277.384. The average price that UCB.BR shares were previous bought at was EUR 208.203. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 482,474 (USD $569,103) compared to the previous valuation of UCB SA |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.77 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.77. The average price that VCYT shares were previous bought at was USD 34.3612. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 13,220 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.11 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.11. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 14,591 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.11 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.11. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 14,591 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.24968 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.24968. The average price that VLA.PA shares were previous bought at was EUR 2.91512. The current market price is 45.8% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 7,505 (USD $8,853) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 6.91 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 6.91. The average price that VNDA shares were previous bought at was USD 4.65578. The current market price is 48.4% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 4,709 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 32.28 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 32.28. The average price that VRDN shares were previous bought at was USD 30.1226. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 16,974 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 20.0645 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 20.0645. The average price that XVIVO.ST shares were previous bought at was SEK 40.1806. The current market price is -50.1% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 1,106 (USD $121) compared to the previous valuation of however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.86 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.86. The average price that ZYME shares were previous bought at was USD 17.6935. The current market price is 51.8% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 4,280 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-12-24 this would crystalise an overall loss. |